Covaxin booster jabs show long-term safety, no serious adverse events: Bharat Biotech
Bharat Biotech says its trial of Covaxin booster jabs has demonstrated "long-term safety with no serious adverse events".
By : migrator
Update: 2022-01-08 14:01 GMT
New Delhi
Bharat Biotech says its trial of Covaxin booster jabs has demonstrated "long-term safety with no serious adverse events"
"90% of recipients had a detectable neutralizing antibody response against the wild-type strain (6 months after the second dose)," the Covaxin maker says.
Visit news.dtnext.in to explore our interactive epaper!
Download the DT Next app for more exciting features!
Click here for iOS
Click here for Android